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Background: Stalled replication forks at common fragile sites are a major cause of genomic instability. RecQ
helicases, a highly conserved family of DNA-unwinding enzymes, are believed to ease ‘roadblocks’ that pose
challenge to replication fork progression. Among the five known RecQ homologs in humans, functions of RECQ1,
the most abundant of all, are poorly understood. We previously determined that RECQ1 helicase preferentially binds
and unwinds substrates that mimic DNA replication/repair intermediates, and interacts with proteins involved in
DNA replication restart mechanisms.
Method: We have utilized chromatin immunoprecipitation followed by quantitative real-time PCR to investigate
chromatin interactions of RECQ1 at defined genetic loci in the presence or absence of replication stress. We have
also tested the sensitivity of RECQ1-depleted cells to aphidicolin induced replication stress.
Results: RECQ1 binds to the origins of replication in unperturbed cells. We now show that conditions of replication
stress induce increased accumulation of RECQ1 at the lamin B2 origin in HeLa cells. Consistent with a role in promoting
fork recovery or repair, RECQ1 is specifically enriched at two major fragile sites FRA3B and FRA16D where replication
forks have stalled following aphidicolin treatment. RECQ1-depletion results in attenuated checkpoint activation in
response to replication stress, increased sensitivity to aphidicolin and chromosomal instability.
Conclusions: Given a recent biochemical observation that RECQ1 catalyzes strand exchange on stalled replication fork
structures in vitro, our results indicate that RECQ1 facilitates repair of stalled or collapsed replication forks and preserves
genome integrity. Our findings provide the first evidence of a crucial role for RECQ1 at naturally occurring fork stalling
sites and implicate RECQ1 in mechanisms underlying common fragile site instability in cancer.
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Inherited syndromes characterized by the replication de-
fects and genomic instability emphasize that DNA replica-
tion and repair must be highly coordinated processes [1].
Deficiencies in DNA replication and repair mechanisms
become particularly detrimental at genomic sequences
that present unique challenges to the replication fork pro-
gression [2,3]. Common fragile sites (CFS) are specific
chromosomal regions, extending over large DNA se-
quences, which are especially prone to genomic instability* Correspondence: sudha.sharma@howard.edu
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reproduction in any medium, provided the orunder conditions of replication stress [4,5]. At fragile sites,
under conditions of replication stress, the replicative poly-
merases may uncouple from the helicase, resulting in long
regions of single-stranded DNA ahead of polymerase that
could pose fork barriers leading to fork disassembly and
DNA breaks [5,6]. CFS are expressed as site-specific gaps
or breaks on metaphase chromosomes after partial inhib-
ition of DNA synthesis, and exhibit sister chromatid ex-
change (SCE), deletions and translocations [5]. Thus, CFS
serve as genomic hot spots for DNA damage and carcino-
genesis [7].
Members of RecQ family DNA helicases, represented by
five homologs (BLM, WRN, RecQ4, RecQ5β and RECQ1)
in humans, are implicated in genome maintenanceThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[8,9]. RecQ helicases are specifically recruited to the sites
of arrested DNA replication where in addition to serving
repair functions, they help stabilize stalled replication
complexes and likely contribute to the S-phase check-
points [10-14]. Importantly, WRN, defective in the prema-
ture aging disease Werner syndrome, has been shown to
regulate fragile site stability [15]. WRN helicase activity
and ATR-mediated checkpoint response collaborate in a
common pathway to maintain CFS stability and WRN-
deficiency is associated with accumulation of gaps and
breaks at CFS [13,15]. In vitro, WRN enhances human
DNA polymerase δ-dependent DNA synthesis through
secondary structure forming sequences within the
FRA16D fragile site [16]. Functions of BLM, defective in
the cancer predisposition disease Bloom syndrome, are es-
pecially important for cells in dealing with replication
stress [12]. WRN and BLM likely perform distinct func-
tions in recovery from fork stalling genome-wide [17], and
collective literature points to their significant roles in
maintaining genomic stability at CFS. Loss of BLM in-
duces 53BP1 nuclear bodies that guard chromosomal fra-
gile sites against genomic instability [18]. Furthermore,
BLM associates with the ultrafine DNA bridges that inter-
link sister chromatids at CFS loci and is required for their
resolution [19]. In fact, human RecQ homologs exhibit di-
verse catalytic activities relevant to replication restart
pathways including disruption of Rad51 presynaptic fila-
ment (BLM and RecQ5β) [20,21], dissolution of double
Holliday junctions (BLM) [22,23], branch migration of
Holliday junctions (BLM, WRN and RECQ1) [24-26] dis-
sociation of mobile D-loops (BLM, RECQ1 and WRN)
[23,27,28], and annealing of complementary single strand
DNA (all five) [29-33]. Functions of RecQ helicases are
therefore likely to be critical under replication stress;
among these, the roles of WRN and BLM remain best
characterized while there is only limited information avail-
able for other RecQ proteins.
RECQ1 (also known as RECQL or RECQL1), the most
abundant of the five human RecQ proteins, was recently
identified as an integral component of replication complex
in unperturbed cells and implicated in maintaining replica-
tion fork progression after initiation [34]. Indeed, recom-
binant RECQ1 binds and unwinds model replication forks
and DNA structure intermediates of recombination [33].
Most recently, RECQ1, similar to WRN, was also shown
to promote strand exchange on synthetic stalled replication
fork-mimicking structures in vitro [35]. Depletion of
RECQ1 reduces cell proliferation and RECQ1-deficient
cells accumulate DNA damage, display heightened sensitiv-
ity to DNA damaging agents that induce stalled and
collapsed replication forks, and exhibit chromosomal in-
stability [36-38]. Evidently, RECQ1-deficient cells are char-
acterized by spontaneous Rad51 foci and elevated SCEs[38] reminiscent of recombinogenic structures proposed to
arise upon replication fork restart following collapse [39].
To investigate a role of RECQ1 in replication fork mainten-
ance, we employed quantitative chromatin immunoprecipi-
tation (ChIP) and examined in vivo chromatin interactions
of RECQ1 in cycling cells following replication inhibition
with hydroxyurea or aphidicolin. We report specific bind-
ing of RECQ1 to two major fragile sites, FRA3B and
FRA16D, in aphidicolin treated HeLa cells. Our results
provide novel evidence and complement existing bio-
chemical data for a role of RECQ1 in genome mainten-
ance upon replication stress.Results
The cellular phenotypes of RECQ1-deficiency and bio-
chemical data suggest a role of RECQ1 in mechanisms
involved in replication stress response. To investigate a
role of RECQ1 in the repair of stalled or collapsed repli-
cation forks, we have evaluated chromatin interaction of
RECQ1 at specific genomic loci in cells exposed to repli-
cation blocking agents.Recruitment of RECQ1 to lamin B2 origin is selectively
enhanced upon replication stress
Silencing of RECQ1 by siRNA leads to reduced cell prolif-
eration [37,40,41]. A key step in the regulation of cell
proliferation is initiation of replication. DNA replication
initiates from a defined initiation site, from which replica-
tion progresses in both directions. One of the best charac-
terized metazoan origins is located at the 3’ end of the
human lamin B2 gene (Figure 1A) [42]. RECQ1 binds to
the lamin B2 origin in unperturbed cells and knockdown
of RECQ1 results in reduced origin firing and defective
replication elongation [34]. To test whether RECQ1 plays a
role in mammalian fork progression after initiation, we in-
vestigated the effects of fork stalling on binding of RECQ1
to lamin B2 origin in HeLa cells by ChIP (Figure 1B, C).
ChIP experiments were done using cells that were either
untreated or treated with hydroxyurea which specifically
inhibits class I ribonucleotide reductase depleting dNTP
pools [43,44] or aphidicolin which is an inhibitor of DNA
polymerase α, δ and ε [45,46] to induce replication forks
arrest. Thus, replication stress induced by hydroxyurea
(2 mM, 24 h) and aphidicolin (0.5 μM, 24 h) treatment
is mechanistically different. Cross-linked chromatin was
immunoprecipitated with a control IgG or a specific anti-
body against RECQ1 that has been successfully used to
identify protein and chromatin interactions of RECQ1
(Figure 1B) [34,47]. Immunoprecipitation of ORC2, a
known lamin B2 origin binding protein and a part of the
pre-replication complex [42], served as positive control
in these experiments. Following cross-link reversal, the
Figure 1 Enhanced enrichment of RECQ1 at lamin B2 origin after replication stress. A. Genomic regions containing the human lamin B2
origin of replication. Primer sets used for qPCR analyses of origin (B48) and non-origin (B13) containing DNA are indicated. B. Quantification of
cross-linked lamin B2 origin immunoprecipitated using the indicated antibodies. HeLa cells were either untreated or incubated with APH (0.5 μM) or HU
(2 mM) for 24 h and processed for ChIP using a RECQ1-specific antibody. ORC2 antibody was used as positive control for origin-enrichment, and rabbit
IgG served as negative control. qPCR was performed with origin-specific and non-origin primers for the lamin B2 locus. Fold enrichment was determined
over IgG and is shown for each primer pair. Results are expressed as means ± SEM for at least three independent experiments. Specificity of RECQ1
antibody in immunoprecipitation (IP) of endogenous RECQ1 from HeLa extract is shown; input represents 10% of the extract used for IP. C. A
representative gel of the amplified DNA immunoprecipitated with indicated antibodies. Input represents 1% of the cross-linked chromatin used for ChIP.
D. Cell cycle profiles of untreated and HU or APH treated (24 h) HeLa cells. Propidium iodide stained cells were analyzed by FACS for DNA content;
distribution in the G1, S, and G2/M phases of the cell cycle is indicated. E. Total RECQ1 protein level in HeLa cells following 24 h treatment with HU
(2 mM) or APH (0.5 μM). GAPDH is loading control. F. Replication stress-dependent chromatin association of RECQ1. Western blot detection of RECQ1 in
chromatin-enriched fractions of untreated and APH (0.5 μM), HU (2 mM) or MMC (0.5 μg/ml) treated cells, or following pretreatment with APH for 4 h
before incubation with MMC (16 h). Histone H3 is loading control and chromatin marker. APH, aphidicolin; HU, hydroxyurea; MMC, mitomycin C.
Lu et al. Molecular Cancer 2013, 12:29 Page 3 of 12
http://www.molecular-cancer.com/content/12/1/29immunoprecipitated chromatin was used to determine the
lamin B2 origin-containing DNA as well as an adjacent re-
gion, B13 that does not contain origin by quantitative real
time PCR (qPCR). ORC2 interacted with lamin B2 origin,
and approximately 4-, 13- and 18-fold enrichment of lamin
B2 origin-specific DNA was found in ORC2 immunopre-
cipitate as compared to IgG in untreated, hydroxyurea, or
aphidicolin treated HeLa cells, respectively (Figure 1B).
Lamin B2 origin-specific DNA was enriched nearly 6-fold
in RECQ1-immunoprecipitate as compared to IgG in un-
treated HeLa cells (Figure 1B). Treatment with replicationinhibitors induced a further enrichment of RECQ1 at
lamin B2 origin; approximately 11- and 30-fold enrichment
of lamin B2 origin specific DNA was obtained in RECQ1
immunoprecipitate as compared to IgG in cells treated
with hydroxyurea or aphidicolin, respectively (Figure 1B).
In comparison, minimal binding to the control B13
containing DNA was observed for ORC2 or RECQ1-
immunoprecipitates (Figure 1B, C). Thus, RECQ1 binds to
the lamin B2 origin of replication in unperturbed HeLa
cells and replication stress significantly enhances origin
binding of RECQ1.
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and is not regulated in cell cycle stage specific manner
[48]; although a small increase is reported in T98G cells
synchronized in S-phase using serum starvation or
mimosine treatment [34]. We monitored cell cycle pro-
gression in HeLa cells utilized in ChIP assay by FACS ana-
lysis (Figure 1D) and also determined total cellular RECQ1
protein level (Figure 1E). Total RECQ1 protein level was
not modulated appreciably in HeLa cells following treat-
ment with hydroxyurea or aphidicolin (Figure 1E). We next
examined cellular RECQ1 in chromatin containing frac-
tions following treatment with agents that introduce repli-
cation fork blocking lesions. HeLa cells either untreated or
treated with hydroxyurea (2 mM, 24 h) or aphidicolin
(0.5 μM, 24 h) were subjected to detergent extraction to
isolate insoluble nuclear pellet containing proteins that
were tightly bound to chromatin and/or nuclear matrix.
RECQ1 protein in untreated cells predominantly fraction-
ated with soluble proteins and only a minor fraction associ-
ated with chromatin in the insoluble nuclear pellet
(Figure 1F). Interruption of DNA synthesis by hydroxy-
urea or aphidicolin resulted in increased RECQ1 in
the insoluble fraction that also contained histones
(Figure 1F). Apparently, increased chromatin associ-
ation of RECQ1 was also seen following treatment
with the DNA inter-strand crosslinking agent mitomy-
cin C (0.5 μg/ml, 24 h) that induces double strand
breaks on encounter with progressing replication fork
(Figure 1F). When replication fork progression was
inhibited by incubating the cells with aphidicolin prior
to mitomycin C treatment, chromatin-bound RECQ1
signal was reduced as compared to mitomycin C alone
but was greater than the untreated cells (Figure 1F).
Thus, stalled and collapsed replication forks induce re-
localization of endogenous RECQ1 to the chromatin.Aphidicolin treatment induces RECQ1 enrichment at CFS
Replication stress particularly affects genomic loci where
progression of replication forks is slow or problematic [2].
To test a putative role of RECQ1 in promoting fork recov-
ery or repair, we examined whether RECQ1 is recruited to
CFS since aphidicolin treatment introduces stalled replica-
tion forks at fragile sites [5]. In order to determine
whether RECQ1 is recruited to stalled replication forks in-
duced at the FHIT region in the aphidicolin-sensitive fra-
gile site FRA3B, HeLa cells were either untreated or
treated with 0.5 μM aphidicolin for 24 h. The cross-linked
chromatin prepared from each condition was then
processed for ChIP by using either control IgG or a spe-
cific RECQ1 antibody. Immunoprecipitation using a spe-
cific antibody against phosphorylated H2AX (γH2AX)
which is known to bind across the FHIT region of FRA3B
served as positive control [18,49]. To determine whetherRECQ1 occupies FRA3B locus, primers specific for two
separate regions in FRA3B fragile locus including the dis-
tal aphidicolin induced breakpoints cluster (FDR) located
within intron 4 of the FHIT gene were used (Figure 2A)
[49,50]. As shown in Figure 2B, RECQ1 or γH2AX did not
bind the FRA3B locus in untreated cells but were
recruited to this fragile site when cells were exposed to
aphidicolin. Treatment with aphidicolin induced enrich-
ment of RECQ1 and γH2AX at FRA3B; approximately
4.5- and 6.5-fold enrichment of FDR-specific DNA was
obtained in RECQ1 and γH2AX immunoprecipitate as
compared to IgG, respectively (Figure 2B, C). RECQ1 and
γH2AX immunoprecipitate also contained a relatively
modest, but reproducible, enrichment of FCR-specific
DNA over IgG, respectively (Figure 2B, C). Thus,
aphidicolin treatment induced an increase in RECQ1
occupancy at the FRA3B fragile site in HeLa cells. ChIP
experiments using hyroxyurea treated cells (2 mM,
24 h) revealed nearly 2.7- and 3.6-fold enrichment of
FDR and FCR-specific DNA in RECQ1 immunoprecipi-
tate as compared to IgG whereas γH2AX immunopre-
cipitate displayed 3- and 2-fold enrichment of FDR and
FCR-specific DNA, respectively (Figure 2D). The rela-
tively reduced binding observed here is likely due to the
fact that hydroxyurea and other inhibitors are less spe-
cific than aphidicolin in inducing lesions primarily at
fragile sites [5].
To ascertain preferential binding of RECQ1 to CFS, we
further analyzed RECQ1 immunoprecipitates by qPCR for
the enrichment of DNA corresponding to FRA16D, the
second most active and aphidicolin-sensitive fragile site in
the human genome (Figure 3A) [51]. As control, we also
examined two non-CFS DNA sequences located within
the GAPDH and β-actin, respectively (Figure 3B, D) [18].
ChIP from untreated HeLa cells did not show enrichment
of FRA16D-specific DNA in RECQ1 immunoprecipitate
relative to IgG suggesting that RECQ1 does not occupy
FRA16D fragile locus in unstressed replicating cells
(Figure 3B). Treatment of HeLa cells with aphidicolin in-
duced recruitment of RECQ1 at the FRA16D locus; ap-
proximately 14-fold enrichment of FRA16D-specific DNA
was obtained in RECQ1 immunoprecipitate as compared
to IgG (Figure 3B). In contrast, only 1.5- and 1.8-fold en-
richment of control sequence spanning GAPDH was
obtained in RECQ1 immunoprecipitate relative to IgG
(Figure 3B, C). As compared to IgG, ChIP of RECQ1,
γH2AX, or ORC2 did not show enrichment of control
sequence spanning β-actin in untreated or aphidicolin
treated cells indicating the specificity of respective anti-
bodies used in these experiments (Figure 3D, E).
Collectively, these experiments demonstrate preferen-
tial and specific binding of RECQ1 to the two well char-
acterized aphidicolin-sensitive fragile sites FRA3B and
FRA16D in response to replication stress.
Figure 2 RECQ1 is recruited to common fragile site FRA3B after treatment with aphidicolin. A. Genomic organization of the FRA3B region.
Primer sets used for qPCR analyses of distal (FDR) and central (FCR) region within the FRA3B locus are indicated. B. Quantification of cross-linked
FRA3B chromatin immunoprecipitated from HeLa cells using the indicated antibodies. HeLa cells were either untreated or treated with
aphidicolin (0.5 μM) for 24 h and then processed for ChIP using a RECQ1-specific antibody. Phosphorylated H2AX (γH2AX) antibody was used as
a positive control for FRA3B enrichment, and rabbit IgG served as negative control in ChIP experiments. qPCR was performed with two different
sets of primers specific for the central and distal regions within FRA3B locus. Fold enrichment over IgG was determined and is shown for each
primer pair for the ChIP. Results are expressed as means ± SEM for at least three independent experiments. C. A representative gel of the
amplified DNA immunoprecipitated with indicated antibodies. Input represents 1% of the cross-linked chromatin used for ChIP. D. Binding of
RECQ1 to FRA3B after treatment with hydroxyurea. Quantification of cross-linked FRA3B chromatin immunoprecipitated from HeLa cells using
the indicated antibodies. HeLa cells were either untreated or treated with hydroxyurea (2 mM) for 24 h and processed for ChIP using a
RECQ1-specific antibody. γH2AX antibody was used as a positive control for FRA3B enrichment, and rabbit IgG served as negative control in ChIP
experiments. qPCR was performed with two different sets of primers specific for the central and distal regions within FRA3B locus. Fold
enrichment over IgG was determined and is shown for each primer pair for the ChIP. Results are expressed as means ± SEM for at least three
independent experiments. APH, aphidicolin; HU, hydroxyurea.
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defective response to replication stress, and
chromosomal fragility
We previously reported that siRNA mediated depletion of
RECQ1 renders HeLa cells more sensitive to camptothecin,
an anti-tumor drug that inhibits the topoisomerase-
induced DNA breakage-reunion reaction resulting in DNA
double strand breaks at stalled replication forks [37]. Given
the enrichment of RECQ1 at aphidicolin-sensitive fragile
sites, we postulated that RECQ1 may be important in
the cellular resistance to aphidicolin. Control or RECQ1
siRNA-transfected cells were exposed to increasing concen-
trations of aphidicolin and their survival was measured
72 h later by MTS assay. In multiple experiments, RECQ1-
depleted HeLa cells displayed increased and dose-dependent sensitivity to aphidicolin when compared to
control siRNA-transfected cells (Figure 4A). Increased
aphidicolin sensitivity of RECQ1-depleted cells was also
observed when proliferation was assayed by cell counting
(Figure 4B). This is consistent with the reported sensitivity
of RECQ1-depleted cells to HU, and other replication
blocking agents [35].
Increased sensitivity to genotoxic agents may be caused
not only by defects in DNA repair but also by disruption
of cell cycle checkpoint responses to DNA damage [52].
ATR-dependent Chk1 phosphorylation is induced to
stabilize replication complexes on stalled forks in cells
treated with aphidicolin or hydroxyurea and the RPA
coated single-stranded DNA is considered to be the pre-
dominant signal for activation of the ATR-Chk1 signal
Figure 3 RECQ1 preferentially binds to FRA16D after treatment with aphidicolin. A. Genomic organization of the FRA16D region. Primer set
used for qPCR analyses of the FRA16D locus is indicated. B. Quantification of cross-linked FRA16D chromatin immunoprecipitated from HeLa cells
untreated or treated with aphidicolin (0.5 μM) for 24 h using a specific RECQ1 antibody or rabbit IgG. Fold enrichment of FRA16D containing
sequences in RECQ1 ChIP was determined by normalizing enrichment obtained with IgG and is shown for both untreated and APH-treated cells.
Relative occupancy of RECQ1 at FRA16D versus a non-fragile negative control site GAPDH shows preferential recruitment of RECQ1 to fragile site
locus in aphidicolin treated cells. Results are expressed as means ± SEM for at least three independent experiments. C. A representative gel of the
amplified DNA immunoprecipitated with indicated antibodies. Input represents 1% of the cross-linked chromatin used for ChIP. D. qPCR analyses
of RECQ1, ORC2 or γH2AX -binding in ChIP experiments to DNA sequence containing β-actin in HeLa cells. E. A representative gel of the
amplified β-actin sequence immunoprecipitated with indicated antibodies. Input represents 1% of the cross-linked chromatin used for ChIP.
APH, aphidicolin.
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blotting Chk1 phosphorylation at Ser317 that is central to
the normal DNA damage response to replication stress
[54]. As compared to control siRNA transfected cells,
RECQ1-depleted HeLa cells exhibit constitutively acti-
vated Chk1 as shown by phosphorylation at Ser317 in the
absence of exogenously induced stress (Figure 4C).
Appearance of RPA32 phosphorylation in undamaged
RECQ1-depleted cells suggests that the checkpoint re-
sponse is triggered by DNA structures generated during
replication such as collapsed replication forks, long
stretches of single-stranded DNA, or unresolved complex
intermediates in RECQ1-deficiency. Pharmacological in-
duction of replication stress revealed aberrant checkpoint
activation in RECQ1-depleted cells (Figure 4C). Hydroxy-
urea treatment (2 mM, 24 h) resulted in the phosphoryl-
ation of Chk1 at Ser317 and RPA32 in control siRNAtransfected HeLa cells (Figure 4C). In contrast, hydroxy-
urea treatment of RECQ1-depleted cells displayed consist-
ently attenuated phosphorylation of Chk1 at Ser317 and
reduced RPA32 phosphorylation (Figure 4C). Reduced
Chk1 phosphorylation was also observed in response to
aphidicolin treatment (0.5 μM, 24 h) in RECQ1-depleted
cells as compared to control HeLa cells (Figure 4C).
RPA32 phosphorylation was not evident in control HeLa
cells upon arresting replication with aphidicolin [55] and a
minimal increase in the signal for RPA phosphorylation
was seen in RECQ1-depleted cells as compared to their
untreated condition (Figure 4C). We observed a modest
increase in signal for γH2AX in untreated and aphidicolin
treated RECQ1-depleted cells as compared to control
siRNA transfected cells (Figure 4C).
Partial inhibition of DNA synthesis by aphidicolin
results in incomplete replication in late replicating
Figure 4 RECQ1-depletion leads to aphidicolin sensitivity, aberrant replication stress response and chromosomal fragility in HeLa cells.
A. Cells transfected with control or RECQ1 siRNA were exposed in quadruplicate to increasing doses of aphidicolin (μM) or grown in regular
complete medium and their survival was measured 72 h later by MTS assay. Percentage of control growth was plotted for each data point,
representing the mean ± SD of three independent experiments. B. Surviving fraction was determined for control or RECQ1 siRNA transfected cells
growing in regular medium or medium supplemented with aphidicolin (μM) by cell count after 72 h and presented as the mean ± SD of three
independent experiments. C. Detection of the activated forms of Chk1 kinase and the phosphorylated forms of RPA32 and H2AX in untreated or
aphidicolin (0.5 μM) treated HeLa cells transfected with control or RECQ1 siRNA. Depletion of RECQ1 by siRNA is also shown. GAPDH serves as
loading control. D and E. Chromosomal breaks/gaps in RECQ1-depleted cells. Metaphase spreads of control or RECQ1 siRNA transected cells
(72 h after siRNA) grown in the absence or presence of aphidicolin (0.5 μM, 24 h) were scored for chromosome gaps/breaks. Ten metaphases of
each cell condition were analyzed. In untreated condition, RECQ1-depleted cells showed significantly more breaks than control cells (p < 0.05);
aphidicolin treatment induced chromosome breaks and gaps in control or RECQ1 siRNA transfected cells (D). Representative partial metaphase
spreads for RECQ1-depletion is shown (E); bottom panel shows an enlarged section. APH, aphidicolin; HU, hydroxyurea.
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ible breaks in metaphase chromosomes [56]. We there-
fore examined whether RECQ1-depletion increases the
basal and aphidicolin-induced metaphase chromosome
breaks. Depletion of RECQ1 led to a significant increase
in the number of chromosome breaks per cell even in
the absence of aphidicolin when compared to the con-
trol siRNA (Figure 4D). This is consistent with spontan-
eous chromosome breaks and gaps observed in RECQ1
knockout mouse embryonic fibroblasts [36] and a re-
cent report using stable knockdown of RECQ1 in hu-
man cells [35].
Given the demonstrated ability of RECQ1 to act upon
replication fork like structures in vitro [33,35], these re-
sults indicate that depletion of RECQ1 as such maycontribute to replication fork collapse and also diminish
recovery from replication arrest.
Discussion
Here we show that conditions of replication stress, spe-
cifically aphidicolin-induced DNA polymerase α, δ and
inhibition, and hydroxyurea-mediated inhibition of ri-
bonucleotide reductase, induce a preferential accumula-
tion of RECQ1 at the lamin B2 origin in HeLa cells.
Consistent with a role in promoting fork recovery or re-
pair, we find that RECQ1 is enriched at two major fra-
gile sites, FRA3B and FRA16D, where replication forks
have stalled following aphidicolin treatment. Moreover,
RECQ1-depletion results in diminished checkpoint acti-
vation in response to replication stress, increased
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These results suggest that RECQ1 is important for
maintaining genomic integrity when DNA replication
forks are slowed by hydroxyurea or aphidicolin and pro-
mote efficient recovery from replication stress.
Results from Thangavel et al proposed that RECQ1 is as-
sembled at origins at the start of bidirectional replication
and is subsequently lost from the origin perhaps still track-
ing along with the newly formed replisome following origin
firing [34]. Consistent with this, we found a significant en-
richment of RECQ1 at origins when replication fork pro-
gression was inhibited by treatment with hydroxyurea or
aphidicolin. Furthermore, our ChIP data show differential
recruitment of RECQ1 at the lamin B2 origin in response
to treatment with aphidicolin (about 30-fold) or hydroxy-
urea (about 11-fold). Aphidicolin has been shown to have
little effect on the activation or initiation of replication ori-
gins and induces uncoupling of replication machinery [57];
it is likely that RECQ1 recognizes the long stretch of
single-stranded DNA produced due to functional uncoup-
ling of the replicative polymerase and helicase complexes
following aphidicolin treatment. Indeed, we found that en-
dogenous RECQ1 displays preferential binding to CFS as
compared to non-fragile control DNA especially after cells
are treated with aphidicolin. CFS represent single-stranded
unreplicated chromosomal regions caused by stalled or
collapsed replication forks [5]. This notion has been sub-
stantiated by investigation of replication timing [58] and
the evidence of involvement of checkpoint proteins ATR
[59,60], BRCA1 [61], SMC1 [62] and FANCD2 [63] in
fragile site stability. Additionally, CFS sequences including
FRA16D are characterized by high AT content, AT-rich
mini satellite repeats and their tendency to form secondary
structures [64]. Human RecQ proteins have demonstrated
ability to resolve a variety of non-B DNA secondary struc-
tures [65]. It is yet unknown whether RECQ1, like WRN
[16], can resolve the predicted cruciform structures at
FRA16D that stall replication fork progression and contrib-
ute to chromosome breakage; however, the fact that
RECQ1 was also enriched at FRA3B that is devoid of mini-
or microsatellite [6] indicates that the secondary structures
alone may not be a sufficient structural element for
RECQ1 binding to the fragile sites. WRN functions at fra-
gile sites are critical but it has not yet been shown whether
WRN is recruited to the fragile site loci in vivo, and
whether it can distinguish fragile and non-fragile regions
under replication stress. RecQ proteins are known to form
multi-protein complexes to execute their functions [14,66],
and it is conceivable that yet unknown protein partners of
RECQ1 recruit and/or mediate its functions at stalled
and broken forks at fragile site loci and elsewhere in
the genome.
Stalled replication fork activates checkpoint signaling
pathways to coordinate cell cycle progression with repairof damage, ensuring the integrity of the genome [52,67].
ATR and Chk1-dependent checkpoints prevent excessive
formation of DNA double strand breaks during replica-
tion arrest [54]. RPA protein complex, consisting of
three subunits RPA72, RPA32 and RPA14, is a first sen-
sor of replication-associated damage and is thought to
signal activation of ATR and thereby trigger an intra-S
checkpoint [68]. Depletion of RECQ1 led to spontaneous
phosphorylation of RPA32 and activation of Chk1; how-
ever, RECQ1-depleted cells are defective in triggering
replication stress response and exhibit sensitivity to rep-
lication blocking agents [35]. During normal DNA repli-
cation, optimal binding of RECQ1 to the origins may
ensure appropriate and accurate genome duplication
during S-phase. Loss of RECQ1 leads to aberrant elong-
ation of progressing replication forks [34] which may
lead to activate the checkpoint response. The fork pro-
moting activity of RECQ1 could be especially important
at naturally occurring DNA sequences such as fragile
sites that are at increased risk for stalling the replication
fork even in the absence of external replication stress.
Our data implicate that RECQ1 also participates in re-
laying signals of fork stalling that help coordinate a
faithful cell cycle and recovery from replication stress.
RECQ1 may contribute to mutational avoidance in un-
perturbed and deliberately stalled replication.
Chromosome breaks observed upon acute depletion of
RECQ1 is consistent with a recent finding that depletion
of RECQ1 activates DNA damage signaling cascade and
accumulates replication-induced double strand breaks
[35]. Conditions that slow replication along the entire
genome, such as aphidicolin treatment, lead to double
strand break formation as a result of fork stalling and
collapse at fragile sites and activate the double strand
break repair pathways [69]. Homologous recombination
is a major mechanism utilized to repair stalled or col-
lapsed replication forks [70]. Importantly, homologous
recombination mechanisms triggered by replication ar-
rest differ from those involved in repairing classical two
ended DNA double strand breaks [71]. Thus, although
the repair of I-Sce induced double strand break was
not significantly modulated by RECQ1-deficiency [47], a
role for RECQ1 in recombination repair of replication-
induced double strand breaks remains possible. In vitro
activity of RECQ1 to unwind synthetic replication fork
and catalyze strand exchange indicates its potential abil-
ity to form and subsequently branch migrate Holliday
junction like recombination structures generated during
template switching at the stalled forks [35,71]. It is con-
ceivable that in the absence of RECQ1, recombinogenic
DNA structures at arrested forks are repaired via hom-
ologous recombination.
Fragile loci often coincide with chromosomal breakpoints
in tumors [5,72]. Given the elevated proliferation status of
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to replication stress are likely to act as caretakers of the
genome during tumor development [12]. A mutation in
RECQ1 has not been linked to a human disease yet, but an
Oncomine database search shows that RECQ1 is over-
expressed in many clinical cancer samples compared to
matched normal samples (Additional file 1: Figure S1).
Similar trend of RECQ1 over-expression across various
tumors is presented by another web database search
(http://medicalgenome.kribb.re.kr/GENT/). It is plausible
that cancer cells position RECQ1 on to specific genomic
loci so as to cope with increased replication-mediated DNA
damage during rapid cell division; in normal cells, RECQ1
can act as a tumor suppressor by facilitating DNA repair
and preventing mutations. This notion is consistent with
the observation that RECQ1 is uniquely important for the
proliferation of cancer cells [37,40,41]. DNA breakage
within CFS is thought to be a consequence of failing to
complete replication and/or resolving the arrested forks
prior to the end of telophase and chromosome segregation
[19]. Recent reports have also suggested that chromosomal
breaks occur at fragile sites because these loci are late repli-
cating and origin poor [73-75]. Whether chromosomal
breaks in RECQ1-deficient cells occur at CFS remains to be
examined, but recruitment of RECQ1 at FRA3B and
FRA16D suggests that RECQ1 either prevents replication
fork stalling within origin poor regions or resolves replica-
tion problems at these CFS. Future experiments will exam-
ine what functional sub-modules of DNA replication are
associated with RECQ1 at specific genomic loci and how
it participates in dynamic response to challenges during
DNA replication. Present findings together with the
in vitro results indicate that impaired response to replica-
tion stress contributes to genomic instability in RECQ1-
deficient cells.
Conclusions
RECQ1, to our knowledge, is the first human RecQ helicase
shown to bind CFS. Overall, our results provide new insight
to RECQ1 functions and contribute to dissecting unique
and overlapping roles of human RecQ homologs in facili-
tating replication fork progression through natural impedi-
ments in genome.
Note added in proof: While this work was under review,
a study by Berti et al. also reported a role of RECQ1 in
replication fork restart [76].
Materials and methods
Cell culture, drug treatment and siRNA transfection
Human HeLa (ATCC) were grown in Dulbecco's modified
Eagle's medium (DMEM) (Invitrogen) supplemented with
10% fetal bovine serum (Hyclone Laboratories), 100 U/ml
penicillin and 100 μg/ml streptomycin (Invitrogen). Cells
were grown in a humidified 5% CO2 incubator at 37°C. Toinduce replication stress, exponentially growing cells
were treated with hydroxyurea (Sigma), aphidicolin
(Calbiochem), mitomycin C (Sigma) as indicated. Deple-
tion of RECQ1 was achieved by transfecting HeLa cells
with a scrambled control siRNA or a SMARTpool of four
distinct siRNA species targeting different regions of
RECQ1 mRNA (siGenome SMARTpool, Dharmacon) at a
final concentration of 10 nM using Lipofectamine 2000
transfection reagent as per the manufacturer’s instructions
(Invitrogen). Knockdown specificity and efficacy of
RECQ1 smartpool siRNA was evaluated by real-time PCR
and Western blotting.
Chromatin immunoprecipitation (ChIP)
HeLa cells were cultured overnight at a density of 1 × 107
per 15 cm diameter dish and subjected to either no treat-
ment or treatment with 0.5 μM aphidicolin for 24 h. Chro-
matin and proteins were cross-linked by incubating cells
in 1% formaldehyde for 15 min at room temperature and
the reaction was stopped by 10 min incubation with
125 mM glycine. Cells were collected and washed sequen-
tially with solution I (10 mM HEPES [pH 7.5], 10 mM
EDTA, 0.5 mM EGTA, 0.75% Triton X-100) and solution
II (10 mM HEPES [pH 7.5], 200 mM NaCl, 1 mM EDTA,
0.5 mM EGTA). The cell pellets were resuspended in 2ml
lysis buffer (25 mM Tris-HCl [pH 7.5], 150 mM NaCl,
0.1% SDS, 1% Triton X-100, 0.5% deoxycholate freshly
supplemented with 1X protease inhibitor cocktail (Roche))
and sonicated on ice by 10 s pulses at 30% of maximal
power on a Misonix 2000 sonicator (Misonix). This sonic-
ation method consistently yielded chromatin fragments
corresponding to an average DNA length of 400-1000 bp
as checked on a 1.5% agarose gel. After centrifugation at
20,000X g for 15 min to remove any debris, the super-
natant was pre-cleared with protein-G-sepharose/salmon
sperm DNA beads (Millipore) at 4°C for 1 h. For each im-
munoprecipitation, 600 μl (equivalent of 3 × 106 cells) of
the pre-cleared chromatin was incubated overnight at 4°C
with 3 μg of antibodies specific for either RECQ1 (Bethyl
Lab, A300-450A), γH2AX (Millipore, 05-636, clone
JBW301), or ORC2 (Enzo Life Science, ADI-KAM-cc235);
antibodies were confirmed for their immunoprecipitation
specificity using Western blot. A reaction containing
an equivalent amount of rabbit IgG was included as
the background control. 10% of the pre-cleared chromatin
was set aside as input control. Antibody-chromatin
complexes were pulled down by adding 50 μl of
protein-G-sepharose/salmon sperm DNA beads and incu-
bated for 2 h at 4°C. The beads were washed for 10 min
each with the following solutions: lysis buffer (as men-
tioned above), high-salt wash buffer (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1], 500 mM
NaCl), LiCl wash buffer (250 mM LiCl, 1% NP-40, 1%
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl [pH 8.0]),
Table 1 Primers used for quantitative real-time PCR
analyses
Name Sequence
B13 Forward 5′- CCCCAGGGAGTAGGTTGTGA-3′
Reverse 5′- TGTTATTTGAGAAAAGCCCAA-3′
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Finally, DNA was eluted with elution buffer (1% SDS,
100 mM NaHCO3). Eluates were incubated at 65°C for
overnight with the addition of 5M NaCl to a final concen-
tration of 200 mM to reverse the formaldehyde cross-
linking and digested at 55°C for 3 h with proteinase K at a
final concentration of 50 μg per ml. Following phenol/
chloroform extraction and ethanol precipitation, sheared
DNA fragments served as template in qPCR analysis.
qPCR were performed using Taq Universal SYBR Green
Supermix (Bio-Rad) with technical triplicates, and thresh-
old cycle numbers (Ct) were determined with an iQ5 ther-
mal cycler (Bio-Rad). Fold enrichment of the targeted
genomic sequences were calculated over IgG as: fold en-
richment = 2 -(Ct IP
− Ct
IgG
), where CtIP and CtIgG are mean
threshold cycles of PCR done in triplicates on DNA sam-
ples immunoprecipitated with specific antibody and con-
trol IgG, respectively. All qPCR reactions were also
checked by melt curve analyses and agarose gel electro-
phoresis to confirm the presence of a single specific prod-
uct. The sequences of the qPCR primers are listed in
Table 1.
Flow cytometry
Cells were collected by trypsinization and fixed with
70% ethanol for 30 min. Cells were subsequently washed
in PBS, treated with RNase in PBS, and resuspended in
PBS with 4 μg/ml propidium iodide. Cells were analyzed
on a FACSCalibur™ flow cytometer from BD Science
using ModFit LT software.
Biochemical fractionation and Western blotting
Chromatin enriched fractions were prepared as previously
described [47] from cells that were either untreated or
treated with indicated concentration of hydroxyurea or
aphidicolin. To obtain total extracts, cells were lysed in
RIPA buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing
cocktail of protease and phosphatase inhibitors (Roche).
Equal amounts of total protein for each sample was run on
8-16% SDS-PAGE and transferred to PVDF membrane for
immunoblotting with antibodies for phospho-Chk1 Ser
317 (Cell Signaling, 2344), γH2AX (Cell Signaling, 2577),
RPA32 (Bethyl Lab, A300-244A), RECQ1 (Bethyl Lab,
A300-450A), GAPDH (Cell Signaling, 2118), and Histone
H3 (Cell Signaling, 4499); all antibodies were used at
1:1000 dilution.
Cell proliferation assay
Cells (24 h after siRNA transfection) were seeded in quad-
ruplicate at a density of 3000 cells/well in 96-well plates
and allowed to adhere for 16 h and subsequently exposed
to increasing concentration of aphidicolin (0-5 μM) and
allowed to grow at 37°C for 3 days in 5% CO2. Cellproliferation was determined by CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay (MTS) (Promega).
Additionally, cells were transfected with the indicated
siRNA, split 1:4 onto a multiwell plate, and grown in the
presence or absence of aphidicolin for further 72 h. The
cells in one well were counted every 24 h for the duration
of the experiment.Metaphase chromosome analyses
Cells, 48 h after transfection, were grown in the presence
or absence of aphidicolin (0.5 μM) for 24 h and treated
with 0.5 μg/ml colchicine for 4 h at 37°C before collection.
To prepare metaphase spreads, cells were resuspended in
hypotonic solution (0.06 M KCl) for 15 min at room
temperature, and then fixed with 3:1 (vol/vol) methanol-
glacial acetic acid. Fixed cell suspension was dropped onto
precleaned microscope slides and air-dried overnight.
Metaphase chromosomes were visualized by Giemsa
staining. Images were documented with a Nikon micro-
scope and at least 10 metaphase chromosome spreads per
treatment were scored in a blinded fashion.
Additional file
Additional file 1: Figure S1. RECQ1 gene expression across many
tumor-normal datasets. The Oncomine™ (Compendia Bioscience, Ann
Arbor, MI) database (http://www.oncomine.org/) was used to
determine how many datasets indicate up-regulation of RECQ1
(also known as RECQL) in cancer versus normal. Top 10% of genes in
the given dataset were considered differentially expressed and the
number of datasets pointing to up or down-regulation of RECQ1 was
counted. A total of 42 out of 391 differential expression analyses
included RECQ1 in the top 10% up-regulation list while only 2 did in
the top 10% down-regulation list.
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